Incyte (INCY) and Genesis Molecular AI announced a significant expansion of their strategic collaboration building and deploying AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement is among the first major pharma-AI collaborations to power large-scale foundation model training with a partner’s proprietary experimental data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte, Edison Scientific announce strategic collaboration to employ Kosmos
- Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
- Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
- Incyte gets orphan designation for treatment of pancreatic cancer
- MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement